Evidence map›Paper›PMID 41542525›Full record

ArticlebioRxiv : the preprint server for biology2026

Novel circadian clock activators display anti-obesity efficacy via suppression of adipocyte development and hypertrophy.

Xuekai Xiong, Jemima Pangemanan, Tali Kiperman, Lu Tang, Zhipeng Fang, Alon Agua, Wendong Huang, David Horne, Ke Ma

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Xuekai XiongDepartment of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010.
Jemima PangemananDepartment of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010.
Tali KipermanDepartment of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010.
Lu TangDepartment of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010.
Zhipeng FangDepartment of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010.
Alon AguaDepartment of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010.
Wendong HuangDepartment of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010.
David HorneDepartment of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010.
Ke MaDepartment of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010.ORCID 0000-0002-5206-1038

Funding

Cancer Metabolism Training ProgramT32CA221709 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI David K. Ann, Victoria L. Seewaldt · 2018 to 2026
$1.8M
Circadian clock and temporal control in nutrient metabolismR01DK137515 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Ke Ma · 2023 to 2026
$1.8M
Circadian Clock Control of Adipose Depot Development and FunctionR01DK112794 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI MA, KE · 2018 to 2021
$1.7M
Circadian clock regulation of metabolic pathways in agingR56AG080294 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI MA, KE · 2023 to 2023
$440k
NCI NIH HHS T32 CA221709NIA NIH HHS R56 AG080294NIDDK NIH HHS R01 DK112794NIDDK NIH HHS R01 DK137515
6 · The paper itself

Abstract

The circadian clock exerts temporal coordination of metabolic processes to maintain homeostasis, and its disruption predisposes to the development of obesity and insulin resistance. Despite the established genetic basis of clock modulation in adipocyte development, whether it can be targeted for anti-obesity interventions remains to be explored. Here we report the novel actions of clock-activating molecules, chlorhexidine and a new derivative CM002, on inhibiting adipocyte development and hypertrophy that results in anti-obesity efficacy

Indexed as

adipocyte developmentadipogenesisCircadian clockdrug developmentobesitysmall molecule

Identifiers

PMID41542525
PMCPMC12803098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.